LUNAR-4: Pilot, Single Arm, Open-Label, Multinational Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated With a PD-1/PD-L1 Inhibitor and Platinum-Based Chemotherapy
Latest Information Update: 30 May 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LUNAR-4
Most Recent Events
- 17 Feb 2025 Planned End Date changed from 1 Oct 2026 to 1 Dec 2026.
- 17 Feb 2025 Planned primary completion date changed from 1 Jun 2026 to 1 Dec 2026.
- 22 Oct 2024 Status changed from not yet recruiting to recruiting.